Drug lookup | Fillwise

METHOTRIMEPRAZINE

All products: not a benefit

Nozinan · DIN 01927671 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.Discontinued 2007-07-18 · checked 2026-09-19

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Nozinan · DIN 01927671 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-07-18 · brand NOZINAN · ATC N05AA02 LEVOMEPROMAZINE · form Tablet · route Oral · ingredients METHOTRIMEPRAZINE (METHOTRIMEPRAZINE MALEATE) 50 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Nozinan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12440 · Verify on the e-Formulary ↗ (DIN 01927671)

Source record

DIN 01927671: Nozinan Raw flags: notABenefit=Y, sec3=Y Item: 282400017; group id 524; item number 1420; lccId None; manufacturer id SAV Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01927671 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12440

Interchangeable products

Methoprazine · DIN 02238406 · $0.4060

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, TRIAZOLAM 28:24 Sedatives and Hypnotics

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24

Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS NOZINAN (methotrimeprazine hydrochloride injection) is indicated for:  Psychotic disturbances: acute and chronic schizophrenias, senile psychoses, manic-depressive syndromes.  Analgesic: In pain due to cancer, zona, trigeminal neuralgia, neurocostal neuralgia, in phantom limb pains, muscular discomforts and as post-operative analgesic adjunct.  Antiemetic: For the treatment of nausea and vomiting of central origin.  Sedative: For the management of insomnia. 1.1 Pediatrics Pediatrics (<1 year of age): Contraindicated See 2 CONTRAINDICATIONS. Pediatrics (1 – 18 years of age): 4.2 4.2 Recommended Dose and Dosage Adjustment 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7 WARNINGS AND PRECAUTIONS, 4.2 4.2 Recommended Dose and Dosage Adjustment NOZINAN is not indicated for the treatment of patients with dementia. See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. https://pdf.hres.ca/dpd_pm/00073362.PDF PM date: NOV 15, 2023 Source product: NOZINAN; DIN 01927698; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Nozinan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026